University of Barcelona, Spain; Catalonian Cancer Plan, Department of Health, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Catalonian Cancer Plan, Department of Health, Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Radiother Oncol. 2022 Apr;169:114-123. doi: 10.1016/j.radonc.2021.08.002. Epub 2021 Aug 27.
BACKGROUND AND PURPOSE: Complex surgery and radiotherapy are the central pillars of loco-regional oncology treatment. This paper describes the reimbursement schemes used in radiation and complex surgical oncology, reports on literature and policy reviews. MATERIAL AND METHODS: A systematic review of the literature of the reimbursement models has been carried out separately for radiotherapy and complex cancer surgery based on PRISMA guidelines. Using searches of PubMed and grey literature, we identified articles from scientific journals and reports published since 2000 on provider payment or reimbursement systems currently used in radiation oncology and complex cancer surgery, also including policy models. RESULTS: Most European health systems reimburse radiotherapy using a budget-based, fee-for-service or fraction-based system; while few reimburse services according to an episode-based model. Also, the reimbursement models for cancer surgery are mostly restricted to differences embedded in the DRG system and adjustments applied to the fees, based on the complexity of each surgical procedure. There is an enormous variability in reimbursement across countries, resulting in different incentives and different amounts paid for the same therapeutic strategy. CONCLUSION: A reimbursement policy, based on the episode of care as the basic payment unit, is advocated for. Innovation should be tackled in a two-tier approach: one defining the common criteria for reimbursement of proven evidence-based interventions; another for financing emerging innovation with uncertain definitive value. Relevant clinical and economic data, also collected real-life, should support reimbursement systems that mirror the actual cost of evidence-based practice.
背景与目的:复杂手术和放疗是局部肿瘤治疗的核心支柱。本文描述了放射肿瘤学和复杂癌症手术中使用的报销方案,并报告了文献和政策审查。
材料与方法:根据 PRISMA 指南,我们分别对放疗和复杂癌症手术的报销模型进行了系统的文献综述。通过对 PubMed 和灰色文献的搜索,我们确定了自 2000 年以来发表的关于放射肿瘤学和复杂癌症手术中当前使用的提供者支付或报销系统(包括政策模型)的文章。
结果:大多数欧洲卫生系统使用基于预算、按服务收费或按部分收费的系统来报销放疗费用;而只有少数系统根据基于事件的模型来报销服务费用。此外,癌症手术的报销模型主要限于 DRG 系统中嵌入的差异以及根据每个手术程序的复杂性对费用进行的调整。各国之间的报销差异很大,导致对相同治疗策略的激励和支付金额不同。
结论:提倡采用基于护理事件作为基本支付单位的报销政策。创新应采用双层方法来解决:一层定义经过验证的基于证据的干预措施的共同报销标准;另一层为具有不确定明确价值的新兴创新提供资金。相关的临床和经济数据,也包括真实世界收集的数据,应支持反映基于证据实践实际成本的报销系统。
Eur J Surg Oncol. 2022-5
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2022-5-20
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2018-9-19
Cochrane Database Syst Rev. 2022-11-11
Front Public Health. 2024-12-19
Ecancermedicalscience. 2023-3-6
Rep Pract Oncol Radiother. 2022-12-29